Source disclosure: January 30, 2026
EIKEN CHEMICAL CO.,LTD. [4549.T]
TOKYO, Jan 30 (Pulse News Wire) – Eiken Chemical CO.,LTD. (4549.T) reported a revenue increase for the third quarter ending March 2026, driven by higher sales of fecal immunochemical test reagents and medical devices, particularly overseas.
Despite rising raw material costs and geopolitical risks, the company maintained its full-year earnings forecast unchanged due to cost efficiency measures and gains from the sale of subsidiary shares in the second quarter. In detail, the company's consolidated revenues reached ¥42.2 billion, up from ¥41.9 billion in the same period last year. Operating profit stood at ¥2.8 billion, reflecting a rise in selling expenses but also benefits from reduced production costs and strategic investments.
Research and development spending was concentrated towards the end of the fiscal year, contributing to sustained profitability. Looking ahead, while global economic uncertainties persist, Eiken remains committed to enhancing operational efficiency through targeted investment in high-margin products and streamlining low-margin offerings. The company’s focus includes optimizing manufacturing processes and improving cash flow management to achieve capital efficiency targets outlined in its medium-term plan.
AI-translated content. 🔴 Confidence: Review recommended See terms • Original filing